AGEN Shares Outstanding History
Below is a table of the AGEN shares outstanding history going back to 10/3/2011:

Date AGEN Shares Outstanding
10/3/20110.02B
11/2/201121.46M
2/24/201222.49M
5/4/201222.79M
8/3/201224.47M
11/2/201224.59M
2/22/201325.30M
5/9/201328.30M
8/5/201329.74M
11/4/201335.47M
2/24/201462.17M
4/30/201462.24M
7/28/201462.68M
10/27/201462.68M
2/24/201570.76M
4/27/201571.49M
7/24/201584.31M
10/30/201584.65M
2/29/201686.52M
5/2/201686.88M
7/29/201687.00M
11/2/201687.13M
2/28/201798.33M
4/26/201799.12M
7/31/201799.71M
11/2/2017100.18M
2/28/2018102.56M
5/4/2018104.00M
8/3/2018113.28M
11/2/2018119.98M
3/11/2019134.21M
5/6/2019134.26M
8/5/2019137.31M
12/31/20182.25M
11/1/2019137.36M
3/12/2020161.59M
5/7/2020169.78M
3/15/2021204.69M

Also see: AGEN Market Cap History
AGEN YTD Return
AGEN Historical Shares Outstanding:
+28.56% CAGR
AGEN Historical Shares Outstanding: +28.56% CAGR

Mouse over chart for data details
10/3/2011 ...3/15/2021
Agenus is a clinical-stage immuno-oncology company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in trials of balstilimab monotherapy and balstilimab/zalifrelimab combination for patients with second-line cervical cancer. Co. is also developing its proprietary anti-CTLA-4 antibody, AGEN1181, which is designed to expand the population of patients benefiting from anti-CTLA-4 therapy. Co.'s AgenTus Therapeutics, Inc. subsidiary focuses on allogeneic cell therapies. We show 38 historical shares outstanding datapoints in our coverage of AGEN's shares outstanding history.

Understanding the changing numbers of AGEN shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like AGEN versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching AGEN by allowing them to research AGEN shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for AGEN:
AGEN SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Agenus (AGEN) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

AGIO Shares Outstanding History
AGLE Shares Outstanding History
AGN Shares Outstanding History
AGRX Shares Outstanding History
AGTC Shares Outstanding History
AHPI Shares Outstanding History
AIMT Shares Outstanding History
AIQ Shares Outstanding History
AKAO Shares Outstanding History
AKBA Shares Outstanding History
More Healthcare companies »

 

AGEN Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.